English

ICOSAVAX, INC.

EDGAR

ICVX Filing amendment (SC 13D/A) · filed 2024-02-21

35 filing records in this dataset, filed from 2021-07-07 to 2024-02-21. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest fiscal year

Revenue

582 thousand USD

2022 · USD

Exact inputs and evidence

Revenue: 582000 USD Source

Operating margin

-16,332.99%

2022 · %

Exact inputs and evidence

Operating Income: -95058000 USD Source
Revenue: 582000 USD Source

Operating cash flow

-61.7 million USD

2022 · USD

Exact inputs and evidence

Operating Cash Flow: -61675000 USD Source

Free cash flow

-72.8 million USD

2022 · USD

Exact inputs and evidence

Operating Cash Flow: -61675000 USD Source
Capital Expenditure: 11113000 USD Source

Cash and cash equivalents: Not available
Long-term debt including current maturities: Not available
Shares outstanding: 50.1 million shares 2023-09-30 Source
Exact value

50088633 shares

Reported share-count change

25.89% · 10.3 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

39787364 shares · 2022-09-30· Source
50088633 shares · 2023-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-96.7 million USD

2022-10-01 – 2023-09-30

Exact inputs and evidence

Net income: -91758000 USD · 2022-01-01 – 2022-12-31 Source
Net income: -68145000 USD · 2022-01-01 – 2022-09-30 Source
Net income: -24561000 USD · 2023-01-01 – 2023-03-31 Source
Net income: -26497000 USD · 2023-04-01 – 2023-06-30 Source
Net income: -22041000 USD · 2023-07-01 – 2023-09-30 Source

Capital expenditure

4.83 million USD

2022-10-01 – 2023-09-30

Exact inputs and evidence

Capital expenditure: 11113000 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 8563000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 1573000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 2252000 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 1573000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 2284000 USD · 2023-01-01 – 2023-09-30 Source
Capital expenditure: 2252000 USD · 2023-01-01 – 2023-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-02-21.

Financial data available through: 2022-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2022-12-31
Operating income: 3 of 11 periods available· newest 2022-12-31
Net income: 3 of 11 periods available· newest 2022-12-31
Operating cash flow: 3 of 11 periods available· newest 2022-12-31
Capital expenditure: 3 of 11 periods available· newest 2022-12-31
Total assets: 3 of 11 periods available· newest 2022-12-31
Total liabilities: 3 of 11 periods available· newest 2022-12-31
Current assets: 3 of 11 periods available· newest 2022-12-31
Current liabilities: 3 of 11 periods available· newest 2022-12-31
cash and cash equivalents: No compatible figures in this window
long term debt: No compatible figures in this window
Shares outstanding: 3 of 11 periods available· newest 2022-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-92.5%

Prior period

USD 7.8 million

2021-01-01 – 2021-12-31
Current period

USD 582,000

2022-01-01 – 2022-12-31

Exact inputs and evidence

582000 − 7802000 = -7220000 USD

7802000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
582000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · ICOSAVAX, INC. · 2022-12-31 ICOSAVAX, INC. (edgar:1786255) Year-over-year change in Revenue: -7220000 USD Concept: fundies:Revenue Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1786255?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 582000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1786255/000095017023010983/icvx-20221231.htm#1622567 Filing: 000095017023010983 Input fundies:Revenue: 7802000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1786255/000095017023010983/icvx-20221231.htm#1624499 Filing: 000095017023010983
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 24.79 million

Prior period

−USD 66.97 million

2021-01-01 – 2021-12-31
Current period

−USD 91.76 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-91758000 − -66971000 = -24787000 USD

-66971000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-91758000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ICOSAVAX, INC. · 2022-12-31 ICOSAVAX, INC. (edgar:1786255) Year-over-year change in Net income: -24787000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1786255?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -91758000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1786255/000095017023010983/icvx-20221231.htm#2334933 Filing: 000095017023010983 Input fundies:NetIncome: -66971000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1786255/000095017023010983/icvx-20221231.htm#2337166 Filing: 000095017023010983
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 23.14 million

Prior period

−USD 38.54 million

2021-01-01 – 2021-12-31
Current period

−USD 61.68 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-61675000 − -38540000 = -23135000 USD

-38540000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-61675000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ICOSAVAX, INC. · 2022-12-31 ICOSAVAX, INC. (edgar:1786255) Year-over-year change in Operating cash flow: -23135000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1786255?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -61675000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1786255/000095017023010983/icvx-20221231.htm#2157966 Filing: 000095017023010983 Input fundies:OperatingCashFlow: -38540000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1786255/000095017023010983/icvx-20221231.htm#2160139 Filing: 000095017023010983
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+1,004.7%

Prior period

USD 1.01 million

2021-01-01 – 2021-12-31
Current period

USD 11.11 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

11113000 − 1006000 = 10107000 USD

1006000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
11113000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ICOSAVAX, INC. · 2022-12-31 ICOSAVAX, INC. (edgar:1786255) Year-over-year change in Capital expenditure: 10107000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1786255?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 11113000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1786255/000095017023010983/icvx-20221231.htm#2165694 Filing: 000095017023010983 Input fundies:CapitalExpenditure: 1006000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1786255/000095017023010983/icvx-20221231.htm#2167858 Filing: 000095017023010983
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2022-01-01 – 2022-12-31

Revenue USD 582,000 100% of revenue
Operating costs Derived USD 95.64 million 16,433% of revenue
Operating income −USD 95.06 million −16,333% of revenue
Tax, interest and other Derived −USD 3.3 million −567% of revenue
Net income −USD 91.76 million −15,766% of revenue

Cash

Operating cash flow −USD 61.68 million −10,597% of revenue
Capital expenditure USD 11.11 million 1,909% of revenue
Free cash flow Derived −USD 72.79 million −12,507% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Operating loss: operating costs were 1,258% of revenue.
2021 Operating loss: operating costs were 944% of revenue.
2022 Operating loss: operating costs were 16,433% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	1616000	20326000 Derived	-18710000	144000 Derived	-18854000	-14219000 Derived	Source 2020-01-01 – 2020-12-31: 1616000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -18710000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -18854000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -14208000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 11000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	7802000	73663000 Derived	-65861000	1110000 Derived	-66971000	-39546000 Derived	Source 2021-01-01 – 2021-12-31: 7802000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -65861000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -66971000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -38540000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 1006000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	582000	95640000 Derived	-95058000	-3300000 Derived	-91758000	-72788000 Derived	Source 2022-01-01 – 2022-12-31: 582000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -95058000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -91758000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -61675000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 11113000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 582K 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	1616000	Revenue: 1616000 Open source
20212021-12-31	Revenue	7802000	Revenue: 7802000 Open source
20222022-12-31	Revenue	582000	Revenue: 582000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-92.5% 2022

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 1616000 Open source
20212021-12-31	Year over year	382.8%	Revenue: 7802000 Open source Revenue: 1616000 Open source
20222022-12-31	Year over year	-92.5%	Revenue: 582000 Open source Revenue: 7802000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -16,333% 2022

Net margin -15,766% 2022

Free cash flow margin -12,506.5% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	-1,157.8%	Operating Income: -18710000 Open source Revenue: 1616000 Open source
20212021-12-31	Operating margin	-844.2%	Operating Income: -65861000 Open source Revenue: 7802000 Open source
20222022-12-31	Operating margin	-16,333%	Operating Income: -95058000 Open source Revenue: 582000 Open source
20202020-12-31	Net margin	-1,166.7%	Net Income: -18854000 Open source Revenue: 1616000 Open source
20212021-12-31	Net margin	-858.4%	Net Income: -66971000 Open source Revenue: 7802000 Open source
20222022-12-31	Net margin	-15,766%	Net Income: -91758000 Open source Revenue: 582000 Open source
20202020-12-31	Free cash flow margin	-879.9%	Revenue: 1616000 Open source Operating Cash Flow: -14208000 Open source Capital Expenditure: 11000 Open source
20212021-12-31	Free cash flow margin	-506.9%	Revenue: 7802000 Open source Operating Cash Flow: -38540000 Open source Capital Expenditure: 1006000 Open source
20222022-12-31	Free cash flow margin	-12,506.5%	Revenue: 582000 Open source Operating Cash Flow: -61675000 Open source Capital Expenditure: 11113000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -61.7M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-14208000	Operating Cash Flow: -14208000 Open source
20212021-12-31	Operating cash flow	-38540000	Operating Cash Flow: -38540000 Open source
20222022-12-31	Operating cash flow	-61675000	Operating Cash Flow: -61675000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -72.8M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	-14219000	Operating Cash Flow: -14208000 Open source Capital Expenditure: 11000 Open source
20212021-12-31	Free cash flow	-39546000	Operating Cash Flow: -38540000 Open source Capital Expenditure: 1006000 Open source
20222022-12-31	Free cash flow	-72788000	Operating Cash Flow: -61675000 Open source Capital Expenditure: 11113000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

8.6% 2022

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	79.2%	Total Liabilities: 12811000 Open source Total Assets: 16170000 Open source
20212021-12-31	Liabilities / assets	3.3%	Total Liabilities: 9409000 Open source Total Assets: 287629000 Open source
20222022-12-31	Liabilities / assets	8.6%	Total Liabilities: 20515000 Open source Total Assets: 238677000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

16.24× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	2.77×	Current Assets: 16160000 Open source Current Liabilities: 5834000 Open source
20212021-12-31	Current assets / current liabilities	31.02×	Current Assets: 286553000 Open source Current Liabilities: 9238000 Open source
20222022-12-31	Current assets / current liabilities	16.24×	Current Assets: 223913000 Open source Current Liabilities: 13788000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	−USD 18.85 million Exact value Exact value: -18854000 USD 2020-01-01 – 2020-12-31: -18854000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ICOSAVAX, INC. · 2020-12-31 ICOSAVAX, INC. (edgar:1786255) Net Income: -18854000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1786255/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -18854000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1786255/000095017022005064/icvx-20211231.htm#2160052 Filing: 000095017022005064 The citation records this snapshot. The page link may show a newer release later.	−USD 14.21 million Exact value Exact value: -14208000 USD 2020-01-01 – 2020-12-31: -14208000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ICOSAVAX, INC. · 2020-12-31 ICOSAVAX, INC. (edgar:1786255) Operating Cash Flow: -14208000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1786255/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14208000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1786255/000095017022005064/icvx-20211231.htm#2000802 Filing: 000095017022005064 The citation records this snapshot. The page link may show a newer release later.	USD 11,000 Exact value Exact value: 11000 USD 2020-01-01 – 2020-12-31: 11000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ICOSAVAX, INC. · 2020-12-31 ICOSAVAX, INC. (edgar:1786255) Capital Expenditure: 11000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1786255/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1786255/000095017022005064/icvx-20211231.htm#2007837 Filing: 000095017022005064 The citation records this snapshot. The page link may show a newer release later.	−USD 14.22 million Calculation and evidence -14208000 − 11000 USD Exact free cash flow: -14219000 USD 2020-01-01 – 2020-12-31: -14208000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 11000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ICOSAVAX, INC. · 2020-12-31 ICOSAVAX, INC. (edgar:1786255) Free cash flow: -14219000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1786255?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14208000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1786255/000095017022005064/icvx-20211231.htm#2000802 Filing: 000095017022005064 Input fundies:CapitalExpenditure: 11000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1786255/000095017022005064/icvx-20211231.htm#2007837 Filing: 000095017022005064 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 66.97 million Exact value Exact value: -66971000 USD 2021-01-01 – 2021-12-31: -66971000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ICOSAVAX, INC. · 2021-12-31 ICOSAVAX, INC. (edgar:1786255) Net Income: -66971000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1786255/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -66971000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1786255/000095017023010983/icvx-20221231.htm#2337166 Filing: 000095017023010983 The citation records this snapshot. The page link may show a newer release later.	−USD 38.54 million Exact value Exact value: -38540000 USD 2021-01-01 – 2021-12-31: -38540000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ICOSAVAX, INC. · 2021-12-31 ICOSAVAX, INC. (edgar:1786255) Operating Cash Flow: -38540000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1786255/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -38540000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1786255/000095017023010983/icvx-20221231.htm#2160139 Filing: 000095017023010983 The citation records this snapshot. The page link may show a newer release later.	USD 1.01 million Exact value Exact value: 1006000 USD 2021-01-01 – 2021-12-31: 1006000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ICOSAVAX, INC. · 2021-12-31 ICOSAVAX, INC. (edgar:1786255) Capital Expenditure: 1006000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1786255/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1006000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1786255/000095017023010983/icvx-20221231.htm#2167858 Filing: 000095017023010983 The citation records this snapshot. The page link may show a newer release later.	−USD 39.55 million Calculation and evidence -38540000 − 1006000 USD Exact free cash flow: -39546000 USD 2021-01-01 – 2021-12-31: -38540000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1006000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ICOSAVAX, INC. · 2021-12-31 ICOSAVAX, INC. (edgar:1786255) Free cash flow: -39546000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1786255?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -38540000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1786255/000095017023010983/icvx-20221231.htm#2160139 Filing: 000095017023010983 Input fundies:CapitalExpenditure: 1006000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1786255/000095017023010983/icvx-20221231.htm#2167858 Filing: 000095017023010983 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 91.76 million Exact value Exact value: -91758000 USD 2022-01-01 – 2022-12-31: -91758000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ICOSAVAX, INC. · 2022-12-31 ICOSAVAX, INC. (edgar:1786255) Net Income: -91758000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1786255/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -91758000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1786255/000095017023010983/icvx-20221231.htm#2334933 Filing: 000095017023010983 The citation records this snapshot. The page link may show a newer release later.	−USD 61.68 million Exact value Exact value: -61675000 USD 2022-01-01 – 2022-12-31: -61675000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ICOSAVAX, INC. · 2022-12-31 ICOSAVAX, INC. (edgar:1786255) Operating Cash Flow: -61675000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1786255/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -61675000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1786255/000095017023010983/icvx-20221231.htm#2157966 Filing: 000095017023010983 The citation records this snapshot. The page link may show a newer release later.	USD 11.11 million Exact value Exact value: 11113000 USD 2022-01-01 – 2022-12-31: 11113000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ICOSAVAX, INC. · 2022-12-31 ICOSAVAX, INC. (edgar:1786255) Capital Expenditure: 11113000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1786255/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11113000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1786255/000095017023010983/icvx-20221231.htm#2165694 Filing: 000095017023010983 The citation records this snapshot. The page link may show a newer release later.	−USD 72.79 million Calculation and evidence -61675000 − 11113000 USD Exact free cash flow: -72788000 USD 2022-01-01 – 2022-12-31: -61675000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 11113000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ICOSAVAX, INC. · 2022-12-31 ICOSAVAX, INC. (edgar:1786255) Free cash flow: -72788000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1786255?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -61675000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1786255/000095017023010983/icvx-20221231.htm#2157966 Filing: 000095017023010983 Input fundies:CapitalExpenditure: 11113000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1786255/000095017023010983/icvx-20221231.htm#2165694 Filing: 000095017023010983 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

35 filings · 673 latest values · 673 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001786255, 1786255, ICVX, edgar:1786255

Also known as ICOSAVAX, INC., Icosavax, Inc.

ICOSAVAX, INC.

Latest fiscal year

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Net income

Capital expenditure

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2022 2022-01-01 – 2022-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation